The blood products company is still looking like a good buy. The post Morgan Stanley just upgraded their CSL share price ...

Nestled into the pines of southern Wake County is the largest cell-based flu vaccine maker in the world. Why it matters: CSL ...

CSL Canada has expanded public reimbursement for ANDEMBRY® (garadacimab), its once-monthly hereditary angioedema prophylaxis, ...

The Australian pharma company believes the drug will be an important therapeutic option to improve kidney function.

Five analyst houses put the 12-month consensus target for CSL at EUR 113.10 on October 14, 2026, according to Boerse Express.

Australian fund managers piled into the one-time blue-chip health giant last month, with the stock now the top position held by local equity fund managers.

CSL Ltd. agreed to pay as much as $1.6 billion to jointly develop and sell an experimental treatment for rare kidney and liver diseases, expanding the Australian biotech company’s push into kidney ...

CSL Group, the leading global provider of Critical Connectivity®, has acquired SIMPL Wireless, the US-based IoT eSIM ...

CSL Ltd (ASX: CSL) has announced a major new drug development partnership. Does the deal make the healthcare share worth buying?